IDSA and HIVMA support the Biden Administration’s decision to declare the monkeypox outbreak a public health emergency.
IDSA and HIVMA support the Biden Administration’s decision to declare the monkeypox outbreak a public health emergency.
As monkeypox cases top more than 5,800 across 48 states, there is no time to waste.
IDSA is pleased to see that critical new investments to strengthen the federal fight against antimicrobial resistance were included in the fiscal year 2023 Labor, Health and Human Services appropriations bill released July 28.
Today’s U.S. Department of Health and Human Services announcement that nearly 800,000 additional doses of the monkeypox vaccine are now available for distribution is a welcome development, but much more is urgently needed.
IDSA and HIVMA appreciate the CDC’s swift action in responding to health care provider concerns regarding the significant procedural barriers required to obtain tecovirimat, or TPOXX, through the Expanded Access for Investigational New Drug program.
The five awarded institutions have created stewardship programs led by infectious diseases-trained physicians and pharmacists that advance science in antimicrobial resistance.
IDSA seeks candidates to serve in the position of editor-in-chief of OFID. The founding editor-in-chief of the journal, Paul Sax, MD, FIDSA, recently departed for a new role as editor-in-chief of IDSA’s journal CID.
With rates of antimicrobial-resistant infections rising quickly, systemic changes are urgently needed to protect public health. This is no longer a future crisis but one that is at America’s doorstep and needs to be addressed now.
FDA’s decision to authorize state-licensed pharmacists to prescribe Paxlovid, within the limitations of and for those indications stated in the emergency use authorization, has the potential to expand access to timely treatment.
IDSA is pleased to see increased funding to strengthen the federal response to antimicrobial resistance, bolster the domestic and global fight against COVID-19, combat the infectious diseases impacts of the opioid crisis and strengthen global security in two recently passed appropriations bills.
As the term of Robert T. Schooley, MD, FIDSA, as editor-in-chief of Clinical Infectious Diseases ends, the Infectious Diseases Society of America wishes to thank him and all members of his editorial board for their extraordinary work as journal and Society leaders.
Increasing access to monkeypox testing and expanding vaccination against infection to people at high risk are needed and welcome steps in efforts to control spread and minimize symptoms.